Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407178 | 0.85 | DRD2 (0.47) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL6246115 | 0.84 | DRD2 (0.46) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL7407894 | 0.83 | GPR84 (0.46) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL7411386 | 0.81 | DRD2 (0.49) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL29460523 | 0.81 | RIPK1 (0.60) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL3492565 | 0.79 | DRD2 (0.58) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL25230913 | 0.77 | DRD2 (0.50) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL2176426 | 0.77 | LOXL2 (0.52) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL13543890 | 0.77 | RIPK1 (0.58) | DRD2DRD4DRD3CCNE1CDK2 | |
| SCHEMBL1939638 | 0.77 | DRD2 (0.50) | DRD2DRD4DRD3CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1281608-C | New AZa-indolyl derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-25 | — | — | CN | disclosed |
| EP-1274711-B1 | NEW AZA-INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-6583134-B2 | Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| CN-1404483-A | New AZa-indolyl derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-19 | — | — | CN | disclosed |
| EP-1274711-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-15 | — | — | EP | disclosed |
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | HOFFMANN-LA ROCHE INC. | 2001-09-27 | — | — | US | disclosed |
| WO-2001066548-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-13 | — | — | WO | disclosed |
| EP-1132389-A1 | New aza-indolyl derivatives for the treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | GPR119, GIPR, INMT | DRD2 514/4885DRD4 347/4885DRD3 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.